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Omega-3 Supplementation CombinedWith Anti–Vascular
Endothelial Growth Factor Lowers Vitreal Levels of
Vascular Endothelial Growth Factor in Wet
Age-Related Macular Degeneration
FLAVIO A. REZENDE, ERIC LAPALME, CYNTHIA X. QIAN, LOIS E. SMITH, JOHN PAUL SANGIOVANNI, AND
PRZEMYSLAW SAPIEHA PURPOSE: To determine the influence of omega-3 sup-
plementation on vitreous vascular endothelial growth fac-
tor A (VEGF-A) levels in patients with exudative
age-related macular degeneration (wet AMD) receiving
intravitreal anti-VEGF treatment.
 DESIGN: Prospective, randomized, open-label, single-
center, clinical trial, consecutive interventional case
series.
 METHODS: The study included 3 cohorts with wet
AMD and a control group with epiretinal membrane or
macular hole. Twenty wet AMD patients being treated
with anti-VEGF were randomized to daily supplementa-
tion of antioxidants, zinc, and carotenoids with omega-3
fatty acids (docosahexaenoic acid and eicosapentaenoic
acid; group 1, n [ 10) or without omega-3 fatty acids
(group 2, n [ 10). They were compared with an anti-
VEGF treatment-naı¨ve wet AMD group (group 3, n [
10) and an epiretinal membrane or macular hole group
(group 4, n [ 10). Primary outcome was vitreal
VEGF-A levels (at the time of anti-VEGF injection). Sec-
ondary outcomes were plasma VEGF-A and central
foveal thickness. Patients with new submacular hemor-
rhage or any other treatment within 3 months were
excluded. Final analyses included 9, 6, 7, and 8 patients
in groups 1 through 4, respectively.
 RESULTS: Patients receiving omega-3s (group 1)
had significantly lower levels of vitreal VEGF-A
(141.11 ± 61.89 pg/mL) when compared with group 2
(626.09 ± 279.27 pg/mL; P [ .036) and group 3
(735.48 ± 216.43 pg/mL; P [ .013), but similar levels
to group 4 (235.81 ± 33.99 pg/mL;P[ .215). All groupsAccepted for publication Jul 27, 2014.
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foveal thickness measurements.
 CONCLUSIONS: This study demonstrated that omega-3
supplementation combined with anti-VEGF treatment is
associated with decreased vitreal VEGF-A levels in wet
AMD patients. (Am J Ophthalmol 2014;158:
1071–1078.  2014 The Authors. Published by
Elsevier Inc. All rights reserved. This is an open access
article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).)
A
GE-RELATED MACULAR DEGENERATION (AMD) IS
the leading cause of blindness in older individuals
in the Western world. The aging of baby boomers
is expected to lead to a 2-fold increase in the number ofwhite
person 65 years of age or older by 2031.1 Correspondingly, a
doubling in the number of North Americans with AMD is
expected. The exudative (wet or neovascular) form of
AMD is associated most widely with central vision impair-
ment and legal blindness.1The15-year cumulative incidence
of wet AMD in Americans 75 years of age or older is 4.4%.2
By 2020, in the United States alone, it is estimated that
nearly 3 million individuals will be affected by wet AMD.3
The progressive nature of wet AMD, its substantial societal
and personal impact, and its high prevalence make it essen-
tial to develop clinical strategies to reduce its impact. It rep-
resents an important cause of morbidity and presents direct
financial burdens of more than $10 billion in direct annual
medical costs in the United States and accounts for signifi-
cant loss of productivity.4 Designing efficient and cost-
effective treatment methods therefore is highly desirable.
The management of wet AMD was revolutionized by the
introduction of anti–vascular endothelial growth factor
(VEGF) therapies.5–7 Regrettably, 5% to 10% of patients
proceed to lose 3 lines or more of visual acuity (VA), and
most exudative lesions show some sign of activity by the
end of follow-up. In addition, increased numbers of thrombo-
embolic events, possible neuronal toxicity, and higher inci-
dence of geographic atrophy in patients with more frequent
anti-VEGF injections also may be of concern.8–10 Thus,
developing alternative or adjunct therapies to currently
available anti-VEGF drugs may increase treatment success,
slow AMD progression, and improve VA outcomes.1071ELSEVIER INC. ALL RIGHTS RESERVED.
The abnormal and disproportionate growth of choroidal
vessels associated with wet AMD likely stems from a
compensatory angiogenic response to overcome an earlier
phase of microvessel degeneration and reinstate metabolic
equilibrium to the hypoxic macula. A potential strategy
to influence and reduce the progression of wet AMD comes
from directly modulating the cellular make-up of the retina.
In this respect, the outer retina is highly concentrated in
diet-derived long-chain polyunsaturated fatty acids
(LCPUFAs)11–13 such as docosahexaenoic acid (DHA) of
the omega-3 family and arachidonic acid of the omega-6
family. The capacity of lipids to play biological roles beyond
energy storage and membrane structure long has been
recognized.13,14 Importantly, dysregulation in lipid
signaling is a salient feature of conditions associated with
chronic inflammation such as metabolic syndrome,
atherosclerosis, asthma, allergic response, autoimmunity,
hypertension, cancer, and importantly in the context of
the current study, ocular vasoproliferative diseases.11,13–18
Because humans are limited in their capacity to bio-
synthesize omega-3 LCPUFAs de novo, their tissue status
is modifiable via diet or supplement intake of DHA and
eicosapentaenoic acid (EPA).14 The benefits of omega-3
supplementation on wet AMD consistently have been
recognized in multiple observational studies,19–23 and
although null results have been reported in a well-
nourished nutrient-supplementing cohort with moderate
to high risk of AMD progression,24 a clearer understanding
of the impact of omega-3 supplementation on wet AMD
could prove beneficial for streamlining therapeutic strate-
gies. Furthermore, a number of fundamental studies have
demonstrated the beneficial effects of omega-3 metabolites
DHA and EPA on pathologic angiogenesis.25–29 Based on
the current experimental and epidemiologic data linking
omega-3 LCPUFAs and their potential beneficial role in
angiogenesis, the purpose of the present pilot trial was to
investigate the influence of omega-3 supplementation on
VEGF-A levels in the vitreous of patients undergoing
anti-VEGF treatment for wet AMD.METHODS
THIS PILOT, PROSPECTIVE, RANDOMIZED, OPEN-LABEL,
single-center clinical trial, consecutive, interventional
case series was conducted between February and August
2011. The study conformed to the tenets of the Declaration
of Helsinki, was approved by the Institutional Review
Board of the Maisonneuve-Rosemont Hospital affiliated
with the University of Montreal, Quebec, Canada,
and is a registered trial (ClinicalTrials.gov identifier,
NCT01819415).
 PARTICIPANTS: Sixty-three patients were screened for
the study. Forty patients were deemed eligible participants1072 AMERICAN JOURNAL OFand were enrolled at the Department of Ophthalmology
Clinic, Maisonneuve-Rosemont Hospital, Montreal, after
providing written informed consent (Figure 1). Three co-
horts consisted of active wet AMD patients (10 per group)
who were eligible for anti-VEGF treatment (bevacizumab
1.25 mg/0.05 mL). They were compared with a non-
AMD group with epiretinal membrane (ERM) or macular
hole (MH; Figure 1). All participants were nonsmokers
with regular consumption less than 1 serving of fish intake
per week, according to a food-frequency questionnaire
applied during recruitment.30
Patients with wet AMD manifesting new thick submac-
ular hemorrhage and those with treatment other than anti-
VEGF or other anti-VEGF drugs within the last 3 months
of study entry were ineligible.
 STUDY GROUPS AND STUDY SUPPLEMENTS: Twenty
patients with active wet AMD who had undergone prior
anti-VEGF treatment were divided in 2 groups and were
randomized to receive oral supplementation as follows:
1. Group 1 (n ¼ 10): Vitalux plus Omega-3 (Alcon,
Toronto, Ontario, Canada) 4 capsules/day; a formula
containing the antioxidants b-carotene (5728 mg),
vitamin C (500 mg), vitamin E (400 IU), zinc
(25 mg), and copper (1 mg), as well as lutein (10 mg),
zeaxanthin (2 mg), and omega 3 (1052 mg fish oil
from sardine, mackerel, and anchovy [200 mg of DHA
and 400 mg of EPA]).
2. Group 2 (n ¼ 10): Vitalux AREDS, 2 capsules/day, a
formula containing the same concentration of antioxi-
dants and minerals, lutein (10 mg), and zeaxanthin
(500 mg; Figure 1).
3. Group 3 (n¼ 10): patients with wet AMD starting anti-
VEGF treatment (treatment naı¨ve).
4. Group 4 (n¼ 10): non-AMD patients with ERM orMH
undergoing 25-gauge pars plana vitrectomy.
Patients from groups 3 and 4 were not taking any of the
above-mentioned supplements.
 ANALYTIC SAMPLE: We consecutively recruited 63 pa-
tients: 53 with wet AMD and 10 with ERM or MH. Of
the wet AMD patients, 23 were excluded because of either
higher omega-3 content in their diets, other anti-VEGF
treatments, or new submacular hemorrhage. Of the 30 pa-
tients recruited with wet AMD, 8 were excluded from sta-
tistical analysis (1 from group 1, 4 from group 2, and 3 from
group 3) because they either had retinal angiomatous pro-
liferation or a large fibrotic component (more than 50%) of
the choroidal neovascularization. Two of 10 patients with
ERM or MH from group 4 also were excluded because
they were found to have diabetes and mild nonproliferative
diabetic retinopathy. A total of 22 patients with wet AMD
(9 in group 1, 6 in group 2, and 7 in group 3) and 8 control
patients were included for VEGF-A analysis (Figure 1).NOVEMBER 2014OPHTHALMOLOGY
FIGURE 1. Diagram showing study participants, including number of recruited, excluded, and analyzed patients. Three wet age-
related macular degeneration (AMD) patient groups, with or without omega-3 supplementation, and a control group are highlighted
in distinct colors. *[wet age-related macular degeneration; **[ epiretinal membrane and macular hole; ***[ retinal angiomatous
proliferation; #[ 1 or more servings of fish per week. ERM or MH[ epiretinal membrane or macular hole; RAP[ retinal angi-
omatous proliferation; Tx[ treatment; VEGF[ vascular endothelial growth factor. END POINTS: The primary outcome was vitreous VEGF-
A levels, and secondary outcomes were plasma VEGF-A
levels and central foveal thickness (CFT) measures. Vitre-
ous and plasma VEGF-A levels were collected at the time
of anti-VEGF treatment. At enrollment, we collected data
on age, gender, number of previous anti-VEGF injections,
time from last anti-VEGF injection, and Snellen visual acu-
ity (converted to logMAR for statistical analysis; Table).
 ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR
TREATMENT PROTOCOL: The anti-VEGF treatment
regimen consisted of 3 loading doses followed by pro re
nata injections based on disease activity measured monthly
by spectral-domain optical coherence tomography (Cirrus,
Carl Zeiss Meditec, Toronto, Canada). Fluorescein angiog-
raphy also was performed on all patients with wet AMD on
the day of the anti-VEGF injection (when vitreous biopsy
and blood samples were collected).
 VITREOUS BIOPSY: After the surgical field was sterilized
using 5% povidone–iodine, patients were draped in a stan-
dard manner with placement of a lid speculum. A 27-gauge
self-retaining infusion line (Insight Instruments, Stuart,
Florida, USA) of balanced salt solution was placed first,
followed by the placement of a 29-gauge trocar with a
chandelier light connected to a mercury vapor light source
(Synergetics, O’Fallon, Missouri, USA). The surgical viewVOL. 158, NO. 5 OMEGA-3 AND ANTI-VEduring the procedure was provided through a surgical oper-
ative microscope and a Volk contact lens (Volk direct
image 31.5 magnifying disposable vitrectomy lens; Volk
Optical, Mentor, Ohio, USA).
The vitreous biopsy was performed using a 23-gauge
sutureless Retrector system (Insight Instruments) in all pa-
tients. The model used in the study is a portable, battery-
powered system with a maximum cut rate of 600 cpm
(cuts per minute) and features a retractable sheathed guil-
lotine 25-gauge cutter with an in-built needle (23 gauge).
The needle was introduced bevel down through displaced
conjunctiva in an oblique 1-plane tunnel into the vitreous
cavity 3 to 4 mm from the limbus. At least 0.5 mL of undi-
luted vitreous fluid was cut and removed from the vitreous
right above the macular region (at the premacular bursa)
through controlled manual aspiration with the Retrector
system. Bevacizumab 2.5 mg/0.1 mL was injected through
the 29-gauge trocar after the vitreous biopsy.31
The samples were split in 3 vials: 1 for VEGF-A levels, 1
for lipidomics analysis, and 1 for microbiologic analysis (to
verify any contamination during vitreous biopsy). The
entire procedure was performed in the minor procedure
room within the Department of Ophthalmology Clinic at
Maisonneuve Rosemont Hospital, Montreal, Canada.
 ASSESSMENT OF VASCULAR ENDOTHELIAL GROWTH
FACTOR A LEVELS: Vitreous and plasma samples were1073GF IN WET AMD
TABLE. Characteristics of Patients and Baseline Parameters of Wet Age-Related Macular Degeneration Groups, With or Without
Omega-3 Supplementation, and the Control Group
Parameter
Wet AMD
Control (Group 4)a P ValueAnti-VEGF Plus Omega-3 (Group 1) Anti-VEGF (Group 2) Anti-VEGF Naı¨ve (Group 3)
Age (y) 79.6 6 1.81 79.00 6 1.98 83.38 6 2.32 68.25 6 3.56 .0099b
No. female (%) 5 (56) 3 (50) 2 (29) 7 (86) .144c
Visual acuityd 0.61 6 0.14 0.84 6 0.17 0.78 6 0.15 n.a. .6606b
No. of previous injections 8 6 1.19 6 6 1.51 n.a. n.a. .5287b
Time from last injection (wks) 8 6 0.40 8 6 0.36 n.a. n.a. .9999b
No. of patients 9 6 7 8
AMD ¼ age-related macular degeneration; n.a. ¼ not applicable; VEGF ¼ vascular endothelial growth factor.
aEpiretinal membrane and macular hole patients.
bStudent t test.
cFisher exact probability test.
dLogarithm of the minimal angle of resolution units.frozen on dry ice and immediately were stored at80 C af-
ter biopsy, then centrifuged at 15 000 g for 5 minutes at 4 C
before analysis. For plasma analysis, 5 mL venous blood was
collected before vitreous biopsy and centrifuged at 3000 g
for 15 minutes at 4 C to obtain plasma and was stored
at 80 C until assayed. VEGF-A levels were
quantified in supernatants using enzyme-linked immuno-
sorbent assays according to manufacturer’s instructions
(R&D Systems, Minneapolis, Minnesota, USA).
 STATISTICAL ANALYSIS: Statistical analysis was
performed using the 2-way analysis of variance nonpara-
metric test, the nonparametric t test (Mann–Whitney U
test), parametric Student t test, and the Student t test
(GraphPad Prism). We applied the Fisher exact probability
test to examine differences in the proportions of women
and men in each group. All statistical analysis were
performed using the same software (GraphPad Prism, La
Jolla, California, USA). Comparisons across all groups
yielded an exact P value of .144, suggesting no appreciable
differences. Respective P values for comparisons of these
proportions across people with wet AMD (groups 1, 2,
and 3), between people with wet AMD in the clinical trial
(group 1 vs group 2) and all people with AMD vs people
with ERM or MH (combined groups 1 through 3 vs group
4) were 0.568, 0.376, and 0.092, respectively. All P values
are 2-tailed. P values less than .05 were considered statisti-
cally significant. Data are expressed as mean 6 standard
error of the mean.RESULTS
BASELINE PARAMETERS WERE SIMILAR FOR EACH GROUP
with the exception that patients in group 4 (control)
were significantly younger than patients with wet AMD
(mean, 68.25 years; standard error of the mean, 3.56, vs1074 AMERICAN JOURNAL OF80.66 6 2.04 years; P ¼ .0099). Patients in groups 1 and
2 had a similar mean (6standard error of the mean) num-
ber of anti-VEGF injections of 8 6 1.19 and 6 6 1.51,
respectively, at the time of their vitreous sampling
(P ¼ .5287). They also had similar values for time from
last injection (86 0.40 vs 86 0.36; P¼ .9999; Table). Pa-
tients with wet AMD did not show any complications
related to the biopsy procedure, and patients in the control
group did not have any complications related to the
25-gauge pars plana vitrectomy surgery.
 PRIMARY OUTCOME: VITREOUS VASCULAR ENDOTHE-
LIAL GROWTH FACTOR A LEVELS: The range of vitreous
concentrations of VEGF-A in patients with wet AMD
was much wider for groups not receiving the omega-3
LCPUFA supplementation. Group 1 (anti-VEGF
injectionsþVitalux plus Omega-3) had significantly lower
levels of VEGF-A in the vitreous when compared with
group 2 (anti-VEGF injections þ Vitalux AREDS without
omega-3 LCPUFAs; P ¼ .036) and group 3 (treatment-
naı¨ve anti-VEGF injections þ no planned supplement
intervention; P ¼ .014), but not when compared with
group 4 (control; P ¼ .215; Figure 2). Both wet AMD
groups not taking omega-3 supplementation (groups 2
and 3) had similar levels of vitreous VEGF-A (P ¼ .758).
Group 3 (treatment naı¨ve) had significantly higher vitre-
ous levels of VEGF-A when compared with nonvascular
ocular pathologic features group 4 (controls; P ¼ .039;
Figure 2). Seven of 9 patients in group 1 had concentra-
tions of vitreous VEGF-A lower than all but 1 of the pa-
tients in group 2 (Figure 2).
 SECONDARY OUTCOMES: Analysis of plasma levels of
VEGF-A revealed no significant change between groups
(P ¼ .736; Figure 3). Similarly, although values for CFT
tended toward improvement, no significant benefit was
noted with omega-3 supplementation in the sample popula-
tion investigated in this pilot study (P ¼ .211; Figure 4).NOVEMBER 2014OPHTHALMOLOGY
FIGURE 2. Graph showing omega-3 supplementation and vitre-
ous vascular endothelial growth factor (VEGF) A concentra-
tions in wet age-related macular degeneration and control
patients. Concentrations of vitreous VEGF-A, demonstrating
that group 1 (anti-VEGF plus omega-3; n[ 9) had significantly
lower levels than group 2 (anti-VEGF alone; n[ 6;P[ .0360)
and group 3 (treatment naı¨ve, starting on anti-VEGF; n [ 7;
P [ .0139). Data also demonstrate that group 1 (anti-VEGF
plus omega-3) and group 4 (control; n[ 8) had similar vitreous
VEGF levels (P [ .2153) and that group 3 (treatment naı¨ve)
had significantly higher vitreousVEGF levels than group 4 (con-
trol; P [ .0387). Group 2 (anti-VEGF alone) and group 3
(treatment naı¨ve), both not taking omega-3 supplementation,
had similar vitreous VEGF levels (P[ .7582, t test).
FIGURE 3. Graph showing omega-3 supplementation and sys-
temic vascular endothelial growth factor (VEGF) A concentra-
tions in wet age-related macular degeneration and control
patients. Plasma VEGF levels demonstrating no significant
difference between group 4 (control; n [ 8) and group 1
(anti-VEGF plus omega-3; n[ 9; P[ .7361), group 2 (anti-
VEGF alone; n[ 6;P[ .6194), and group 3 (treatment naı¨ve,
starting on anti-VEGF; n[ 7; P[ .9474, t test).DISCUSSION
IN THIS PILOT CLINICAL TRIAL, WE INVESTIGATED THE IN-
fluence of omega-3 supplementation on VEGF-A levels
in the vitreous of patients undergoing anti-VEGF treat-
ment for wet AMD and noted a significant decrease of
VEGF-A in patients receiving omega-3. Dietary intake of
omega-3 LCPUFAs and its influence on processes impli-
cated in pathologic retinal angiogenesis has been pro-
posed.18 We previously reported on the pronounced
anti-angiogenic effects of certain omega-3 LCPUFA
metabolites such as 4-hydroxy-docosahexaenoic acid
(a metabolite produced via the 5-lipoxygenase pathway
and acting through the peroxisome proliferator-activated
receptor). We also demonstrated that increased omega-3
LCPUFA dietary intake reduces pathologic angiogenesis
in experimental animal models of neovascular retinopa-
thies.27,29,32 Our previous genetic work in humans
extended these findings to support the influence of
omega-3 activated pathway on angiogenesis in wet AMD
patients via complement and VEGF signaling systems.33
In the time frame of the current human study, the effects
of omega-3 supplementation were exclusive to modulating
vitreous levels of VEGF-A in proximity of the site of
neovascularization, but not on systemic levels as deter-
mined by analysis of plasma.
Interestingly, despite the significantly lower levels of
VEGF-A in the vitreous of group 1, CFT values were
similar to those of group 2 (after an average of 7 priorVOL. 158, NO. 5 OMEGA-3 AND ANTI-VEanti-VEGF injections) and of group 3 (Figure 3 and
Table). In accordance with recent work in diabetic macular
edema by Sonoda and associates, our findings also demon-
strated a lack of correlation between CFT values and vitre-
ous levels of VEGF in patients with active wet AMD (data
not shown).34 These data agree with the notion that other
factors besides VEGF-A may contribute to disease activity
in wet AMD and that combination therapy with other
agents is likely necessary in many patients to completely
stall CNV activity and promote regression. In addition,
the bevacizumab pro re nata treatment protocol used for
groups 1 and 2 may have contributed to the absence of sig-
nificant variations in plasma levels of VEGF-A when
compared with group 3 (treatment naı¨ve). Lesser influence
of bevacizumab treatment on systemic levels of VEGF also
has been found in patients in the discontinuous treatment
arm of the Inhibit VEGF in Age-related choroidal Neovas-
cularization (IVAN) trial.35
The biopsy technique applied was performed specifically
to collect vitreous samples as close as possible to the mac-
ula, under microscope visualization, to obtain a representa-
tive vitreal sample in close proximity to neovascular
membranes.31 This accurate sampling by vitreous biopsy
directly adjacent to the macula also may explain in part
the higher levels of VEGF-A detected in our patients
with wet AMD when compared with previous reports.36,37
Despite high levels of LCPUFA metabolites in retinal
tissue,29 lipidomic analysis of the undiluted vitreous in
wet AMD did not yield consistent results, and we were
not able to detect consistent levels of omega-3 and
omega-6 metabolites (data not shown).
Epidemiologic studies consistently have shown protec-
tive relationships of increased omega-3 LCPUFA-rich
food intake with advanced AMD.19–23 The Age-Related1075GF IN WET AMD
FIGURE 4. Graph showing omega-3 supplementation and cen-
tral foveal thickness in wet age-related macular degeneration
and control patients. Assesment of central foveal thickness
showed no significant difference between group 1 (anti–vascular
endothelial growth factor [VEGF] plus omega-3) and group 2
(anti-VEGF alone;P[ .2108), group 3 (treatment naı¨ve, start-
ing on anti-VEGF; P [ .1511), and group 4 (control;
P[ .9579, t test).Eye Disease Study 2 did not report a protective effect of
350 mg/day of DHA plus 650 mg/day of EPA supplementa-
tion for progression to wet AMD in their phase 3 clinical
trial.24 The lack of positive results in this trial could be
because it was performed on a very well-nourished study
population, in which 11% of the placebo group were taking
omega-3 LCPUFAs outside the study regimen, or that a
higher supplemental dose or higher composition of DHA
plus EPA was needed for efficacy.24
The Nutritional AMD Treatment 2 study research team
randomly assigned high-risk AMD patients to 840 mg/day
DHA plus 270 mg/day EPA or a placebo for 3 years.
Time to occurrence of CNV did not differ between
omega-3 vs placebo groups; however, patients in the group
receiving omega-3 LCPUFAs were in the higher tertile of
the area under the receiver operating characteristic curve
for serum and red blood cell membrane levels of DHA1076 AMERICAN JOURNAL OFplus EPA and had nearly a 70% lower risk of developing
CNV when compared with the lower tertile.38
The limitations of the current pilot study include its
small sample size, the inability to detect vitreal lipid pro-
files, lack of DHA serum levels measurements, and perhaps
low doses of omega-3 LCPUFAs in supplements.
In summary, we demonstrated that daily omega-3 fatty
acid supplementation as part of a formulation also contain-
ing antioxidants, zinc, lutein, and zeaxanthin in patients
with wet AMD and being treated with anti-VEGF injec-
tions (group 1) was associated with significantly lower vit-
reous levels of VEGF-A than those observed in patients
treated with bevacizumab plus daily omega-3-free supple-
ments (group 2). Anti-VEGF–naı¨ve eyes without any
nutrient supplement and an omega-3 LCPUFA poor diet
(group 3) also were associated with higher VEGF-A levels
than those detected in the omega-3 supplemented group
(group 1). Furthermore, we showed that omega-3 supple-
mentation specifically lowers vitreous levels of VEGF-A
without influencing plasma levels of VEGF-A in patients
with wet AMD who were receiving a bevacizumab pro re
nata regimen. This is likely because AMD provokes a local
rise in VEGF-A, and hence only vitreous, but not systemic,
levels increase. The average time from last injection in
both groups being treated with bevacizumab was 8 weeks,
without any significant difference between groups 1 and
2 (Table). Although recent studies have demonstrated
decreased systemic VEGF levels up to 4 weeks after intra-
vitreal bevacizumab injection, our study did not show
any significant difference between groups 1 and 2 (treated
with bevacizumab) and group 3 (treatment naı¨ve) at
8 weeks after their last anti-VEGF injection.39,40
Therefore, our data suggest that omega-3 supplementation
selectively lowers pathologic ocular VEGF-A in the retina,
but not physiologic systemic VEGF-A. Long-term studies
will be required to determine if the observed reduction
in VEGF-A by omega-3- supplementation combined
with anti-VEGF translates into lesser CNV progression
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